BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
4.110
-0.220 (-5.08%)
At close: Dec 5, 2025, 4:00 PM EST
4.090
-0.020 (-0.49%)
After-hours: Dec 5, 2025, 7:52 PM EST

Company Description

BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia.

The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding.

It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process.

The company’s products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing.

It also develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers.

BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

BioNexus Gene Lab Corp.
BioNexus Gene Lab logo
Country Malaysia
Founded 2017
Industry Specialty Chemicals
Sector Materials
Employees 30
CEO Su-Leng Tan

Contact Details

Address:
Menara UOA Bangsar, Unit A-28-7, Level 28, Tower A
Kuala Lumpur, 59000
Malaysia
Phone 60 1 307 241 6898
Website bionexusgenelab.com

Stock Details

Ticker Symbol BGLC
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001737523
CUSIP Number 090628306
ISIN Number US0906283066
Employer ID 26-2124961
SIC Code 8071

Key Executives

Name Position
Su-Leng Tan Chief Executive Officer, President, Secretary and Director
Set Fui Chong Chief Financial Officer
Kwan Wah Chan Marketing Manager
Too Kam Tham Managing Director

Latest SEC Filings

Date Type Title
Dec 3, 2025 DEF 14A Other definitive proxy statements
Dec 2, 2025 8-K Current Report
Nov 14, 2025 10-Q Quarterly Report
Nov 14, 2025 PRE 14A Other preliminary proxy statements
Nov 13, 2025 8-K Current Report
Nov 12, 2025 8-K Current Report
Nov 7, 2025 S-3 Registration statement under Securities Act of 1933
Oct 23, 2025 8-K Current Report
Aug 18, 2025 10-Q Quarterly Report
Aug 14, 2025 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB